Gapping up
In reaction to earnings/guidance:
- SNBR +12.7%, TWLO +10.1%, WK +8.2% (also CFO to retire), MANT +6.7% (also increases dividend), TSLX +5.9%, BCOV +5.7%, CYH +5.5%, NTR +5.4% (also increases dividend slightly, approves repurchase of 5% of shares), EIG +5.2%, MX +5%, SKT +4.8%, FVRR +3.8%, LXP +3.8%, WST +3.5%, TECK +3%, CTRN +2.8%, TLRY +2.6%, NVTA +2.3%, RGR +2.2%, PAAS +2%, GFI +2%, MOS +1.9%, GOLD +1.9%, GTLS +1.9%, IAG +1.8%, LOPE +1.6%, CAKE +1.4%, LASR +1.2%, CBZ +1.1%, LKQ +1%
Other news:
- CAPA +57.2% (HighCape Capital Acquisition Corp and Quantum-Si entered into a definitive business combination agreement)
- CBLI +29.2% (files Form S-4 in connection with its previously announced merger agreement with Cytocom)
- RIGL +25.2% (Eli Lilly and Rigel Pharmaceuticals (RIGL) announce a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, for all indications including autoimmune and inflammatory diseases)
- SFTW +19.6% (Osprey Technology Acquisition Corp enters into definitive agreement for business combination with BlackSky Holdings, resulting in BlackSky becoming publicly listed company)
- NEPT +5.2% (announces favorable decision in dispute with Azpa Pharmaceuticals)
- CPG +4.8% (to acquire Shell's Kaybob Duvernay assets in Alberta for $900 mln)
- CGNT +4.2% (move attributed to positive Whitney Tilson mention)
- PRVB +4.1% (announces collaboration to commercialize PRV-3279 in Greater China)
- IMUX +4% (reports "positive" top-line data from investigator-sponsored phase 2 clinical trial of IMU-838 in primary sclerosing cholangitis)
- SEEL +3.9% (signs amendment to repurchase portion of royalties for SLS-002)
- CSV +2.8% (extends term of employment agreement for CEO)
- OZON +2.4% (announces the final pricing of the offering of $750 mln in aggregate principal amount of senior unsecured convertible bonds due 2026)
- AXGN +1.9% (completes pilot phase analysis for REPOSE clinical study)
- RDHL +1.8% (announces manufacturing agreements with Cosmo Pharmaceuticals for Movantik and RHB-204)
- VTVT +1.4% (initiates phase 1 study for HPP737)
- MTDR +1.3% (reports 7% yr/yr increase in total proved reserves)
- EQH +1.3% (authorizes $1 bln share repurchase program)
- MYOV +1.3% (MYOV and PFE announce journal publication for Phase 3 LIBERTY studies), .
Analyst comments:
- WFC +0.7% (upgraded to Neutral from Underweight at JP Morgan)
- SNDX +0.7% (initiated with a Buy at B. Riley Securities)
- TENB +0.6% (resumed with a Buy at Stifel)
- INFY +0.5% (initiated with an Overweight at Piper Sandler)